[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Gellermann J, Hildebrandt B, Issels R, Ganter H, Wlodarczyk W, Budach V, Felix R, Tunn PU, Reichardt P, Wust P: Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry. Cancer; 2006 Sep 15;107(6):1373-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry.
  • BACKGROUND: The objective of this study was to evaluate noninvasive magnetic resonance (MR) thermography for the monitoring of regional hyperthermia (RHT) in patients with soft tissue sarcomas of the lower extremities and pelvis.
  • METHODS: Noninvasive MR monitoring during RHT was performed in 9 patients who had high-risk soft tissue sarcomas of the lower extremities or pelvis during neoadjuvant chemotherapy plus RHT in the scope of the European Organization for Research and Treatment of Cancer 62961/European Society for Hyperthermic Oncology RHT-95 study.
  • Anatomic and temperature-sensitive data sets were acquired every 10 minutes before and during RHT (using gradient-echo-sequences with variable echo times).
  • A phase convolution setting phase shifts to zero in the fat tissue was performed as a drift correction.
  • The mean MR temperatures in the tumor and muscles and the index temperatures (e.g., T90, which covers 90% of the target volume) and thermal doses were determined and compared with pathohistologic responses and direct temperature measurements if available.
  • The correlation of 13 conventional temperature measurements performed in selected patients and sessions invasively in the tumor or noninvasively in rectum and bladder revealed an excellent correlation with MR temperatures (R2 = .96).
  • CONCLUSIONS: Noninvasive MR thermography of soft tissue sarcoma was feasible and suitable for validating the quality of heating during RHT.
  • [MeSH-major] Hyperthermia, Induced. Magnetic Resonance Imaging / methods. Sarcoma / therapy. Thermography / methods
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Body Temperature. Chemotherapy, Adjuvant. Combined Modality Therapy. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Monitoring, Physiologic / instrumentation. Monitoring, Physiologic / methods. Reproducibility of Results. Treatment Outcome

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • (PMID = 16902986.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


2. Ferrari A, Bisogno G, Macaluso A, Casanova M, D'Angelo P, Pierani P, Zanetti I, Alaggio R, Cecchetto G, Carli M: Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1. Cancer; 2007 Apr 1;109(7):1406-12
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue sarcomas in children and adolescents with neurofibromatosis type 1.
  • BACKGROUND: Patients affected by neurofibromatosis type 1 (NF1) are at higher risk of developing soft-tissue sarcomas (STS) than the general population.
  • METHODS: The study included 37 patients with neurogenic sarcomas (36 malignant peripheral nerve sheath tumors [MPNST], 1 triton tumor) and 6 cases of rhabdomyosarcoma (RMS).
  • Two of 16 patients with evaluable disease responded to chemotherapy.
  • All 6 RMS patients were </=3 years old and had embryonal subtype, 5 of 6 arising in the genitourinary tract or pelvis (paravesical); 4 were alive in first remission at the time of the analysis, 1 was alive in second remission after a local recurrence, and 1 died of disease.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Male. Neoplasms, Second Primary / complications. Neoplasms, Second Primary / diagnosis. Neoplasms, Second Primary / therapy. Nerve Sheath Neoplasms / complications. Nerve Sheath Neoplasms / diagnosis. Nerve Sheath Neoplasms / therapy. Neurofibrosarcoma / complications. Neurofibrosarcoma / diagnosis. Neurofibrosarcoma / therapy. Peripheral Nervous System Neoplasms / complications. Peripheral Nervous System Neoplasms / diagnosis. Peripheral Nervous System Neoplasms / therapy. Prognosis. Prospective Studies. Rhabdomyosarcoma / complications. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / therapy. Risk Factors. Survival Rate

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17330850.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


3. Vukasinović Z, Spasovski D, Slavković N, Slavković S, Zivković Z: [Chondroblastoma--current opinion]. Srp Arh Celok Lek; 2006 Nov-Dec;134(11-12):567-70
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chondroblastoma of bone is rare bone tumor, representing around 1% of benign bone lesions.
  • Predilection sites include proximal humeral epiphysis, femoral and tibial condyles, but it can be found in other bones, too (skull, pelvis, posterior vertebral structures, tarsal bones).
  • Pathohistologically, it is described as highly cellular tissue, variably differentiated and with discrete granulated to meshy calcification of the matrix and large multinuclear cells present in 20% of cases.
  • Tumor is presented with a few nonspecific local symptoms, which makes diagnostic procedure more difficult.
  • Definitive diagnosis is made only by pathohistological verification.
  • The treatment of chondroblastoma is strictly surgical, with a view to counteract the propagation into the joint or adjacent soft tissue, and diminish the recurrence rate.
  • Chemotherapy is not indicated for treatment of this tumor, and radiotherapy is contraindicated as it stimulates malignant alteration.
  • If malignant chondroblastoma of bone is verified pathohistologically, radical treatment by surgical resection is indicated, also avoiding any adjuvant therapy.

  • Genetic Alliance. consumer health - Chondroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304775.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Serbia and Montenegro
  • [Number-of-references] 34
  •  go-up   go-down


Advertisement
4. Saab R, Rao BN, Rodriguez-Galindo C, Billups CA, Fortenberry TN, Daw NC: Osteosarcoma of the pelvis in children and young adults: the St. Jude Children's Research Hospital experience. Cancer; 2005 Apr 01;103(7):1468-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma of the pelvis in children and young adults: the St. Jude Children's Research Hospital experience.
  • The median patient age at diagnosis was 16.8 years.
  • Four tumors were secondary to radiation therapy.
  • Five patients had metastases in the lung (n = 4 patients) or bone (n = 1 patient) at diagnosis.
  • The median greatest tumor dimension for the 13 tumors with known size was 10 cm.
  • Of the three patients who survived disease-free, one patient underwent complete resection, one patient underwent incomplete resection (nonviable tumor at the soft tissue margin) with a good response to chemotherapy, and one patient with a sacral tumor underwent radiotherapy only for local control.
  • All patients with metastatic disease at diagnosis died.
  • New therapeutic approaches are needed.
  • [MeSH-major] Osteosarcoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Pelvic Neoplasms / diagnosis. Pelvic Neoplasms / therapy. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 American Cancer Society.
  • (PMID = 15739209.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R25 CA023944; United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-23099
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


5. Henshaw RM, Priebat DA, Perry DJ, Shmookler BM, Malawer MM: Survival after induction chemotherapy and surgical resection for high-grade soft tissue sarcoma. Is radiation necessary? Ann Surg Oncol; 2001 Jul;8(6):484-95
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival after induction chemotherapy and surgical resection for high-grade soft tissue sarcoma. Is radiation necessary?
  • BACKGROUND: Induction chemotherapy can produce dramatic necrosis in sarcomas-raising the question of whether or not radiation is necessary.
  • This study reviews the clinical outcome of a subset of patients with high-grade extremity soft tissue sarcomas (STS) who were treated with induction chemotherapy and surgical resection but without radiation.
  • METHODS: Nonmetastatic, large, high-grade STS of the pelvis and extremities were treated with intra-arterial cisplatin, adriamycin, and, after 1995, ifosfamide.
  • Median tumor necrosis was 95%.
  • Four patients developed metastatic disease with three subsequent deaths.
  • CONCLUSIONS: Intensive induction chemotherapy can be extremely effective for high-grade STS, permitting limb-sparing surgery in lieu of amputation.
  • Radiation may not be necessary if a good response to induction chemotherapy and negative wide margins are achieved.
  • All patients with large, deep, high-grade STS of the extremities should be considered candidates for induction chemotherapy.
  • [MeSH-major] Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / surgery. Sarcoma / drug therapy. Sarcoma / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Extremities / pathology. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoadjuvant Therapy. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2001 Jul;8(6):480-1 [11456046.001]
  • (PMID = 11456048.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Dantonello TM, Int-Veen C, Leuschner I, Schuck A, Furtwaengler R, Claviez A, Schneider DT, Klingebiel T, Bielack SS, Koscielniak E, CWS study group, COSS study group: Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups. Cancer; 2008 Jun;112(11):2424-31
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups.
  • BACKGROUND: Mesenchymal chondrosarcoma (MCS) is a rare tumor with a strong tendency toward late recurrences leading to reported 10-year survival rates below 50%.
  • The recommended treatment is resection with wide margins; the effectiveness of chemo- and radiotherapy remain poorly defined.
  • As reports about MCS in young patients are scarce, treatment and outcomes of children/adolescents/young adults in the CWS and COSS studies were investigated.
  • METHODS: Since 1977, 15 of >7000 CWS and COSS patients <or=25 years had a confirmed diagnosis of MCS.
  • Tumor sites were head/neck (n = 6), paravertebral (n = 3), pelvis (n = 3), limbs (n = 2), and kidney (n = 1).
  • Thirteen individuals received chemotherapy, 6 were irradiated.
  • Four recurrences occurred, all within 4 years from diagnosis (3 local, 1 combined; 2 of these in irradiated patients).
  • Seven of 8 patients whose tumors were completely resected during primary treatment, but only 4 of 7 patients with incomplete surgery survived disease-free.
  • CONCLUSIONS: This series of 15 MCS differs from others: the median age was young, most tumors were extraosseous, most patients received chemotherapy, and the outcome was better than published.
  • Treating MCS according to standard multimodal soft tissue/bone sarcoma regimens is proposed.
  • [MeSH-major] Bone Neoplasms / pathology. Chondrosarcoma, Mesenchymal / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Infant. Male. Neoplasm Staging. Prospective Studies. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Chondrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 American Cancer Society.
  • (PMID = 18438777.001).
  • [ISSN] 1097-0142
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


7. Raney B, Stoner J, Anderson J, Andrassy R, Arndt C, Brown K, Crist W, Maurer H, Qualman S, Wharam M, Wiener E, Meyer W, Hayes-Jordan A, Soft-Tissue Sarcoma Committee of the Children's Oncology Group: Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children's oncology group. J Pediatr Surg; 2010 Nov;45(11):2160-8
MedlinePlus Health Information. consumer health - Diagnostic Imaging.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of tumor viability at second-look procedures performed before completing treatment on the Intergroup Rhabdomyosarcoma Study Group protocol IRS-IV, 1991-1997: a report from the children's oncology group.
  • PURPOSES: The aims of the study were to compare results of clinical/radiographic studies before second-look procedures (SLP) with SLP specimens from patients with gross residual sarcoma at diagnosis and to relate tumor viability to outcome.
  • PATIENTS: Seventy-three patients underwent SLP before completing chemotherapy, with (n = 59) or without (n = 14) radiotherapy.
  • Tumor sites were bladder/prostate (n = 27), head/orbit/parameningeal (n = 22), extremity/trunk (n = 14), and retroperitoneum/pelvis (n = 10).
  • RESULTS: Of 14 patients, 1 (7%) with clinical/radiographic complete response (CR) had viable tumor.
  • Of 59 patients, 35 (59%) without CR had viable tumor.
  • Five-year failure-free survival (FFS) rates were 81% in 37 patients without viable tumor and 53% in 36 patients with viable tumor (Cox proportional hazards adjusted P = .05).
  • Five-year FFS rates were 67% in 15 patients with clear margins and 43% in 21 patients with tumor-involved margins (n = 18) or viable gross tumor (n = 3) (Cox proportional hazards adjusted P = .04).
  • Five-year survival was 78% to 79% among 73 patients with and 333 patients without SLP during treatment.
  • CONCLUSIONS: Second-look procedures can show whether viable tumor is present and may be beneficial in selected patients with rhabdomyosarcoma.
  • Disappearance of tumor (CR) usually correlated with no viable tumor at SLP.
  • However, 41% of patients without CR had no viable tumor.
  • Those without viable tumor had increased FFS but not survival compared to those with viable tumor.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier Inc.
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Sep;28(9):563-7 [17006261.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3705-11 [19470937.001]
  • [Cites] Pediatr Blood Cancer. 2008 Nov;51(5):593-7 [18668515.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Med Pediatr Oncol. 1994;22(1):22-6 [8232076.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1904-22 [8448756.001]
  • [Cites] Acta Oncol. 1989;28(1):67-72 [2706134.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] J Urol. 2004 Jun;171(6 Pt 1):2396-403 [15126860.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1974-80 [12673726.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):718-28 [11597814.001]
  • (PMID = 21034938.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-98543; United States / NCI NIH HHS / CA / U10 CA072989; United States / NCI NIH HHS / CA / U10 CA029511; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-72989; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA-29511; United States / NCI NIH HHS / CA / U10 CA024507
  • [Publication-type] Clinical Trial, Phase IV; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS265975; NLM/ PMC3128803
  •  go-up   go-down


8. Ozger H, Bulbul M, Eralp L: Complications of limb salvage surgery in childhood tumors and recommended solutions. Strategies Trauma Limb Reconstr; 2010 Apr;5(1):11-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bone and soft tissue malignancies are associated with serious diagnostic and therapeutic problems in every level of pubertal growth in children.
  • Current treatment modality preferred in bone and soft tissue tumors is wide resection of tumor followed by the reconstruction of consequent defect by various methods.
  • Chemotherapy and radiotherapy are applied for systemic effects to the patient pre- and post-operatively and for local effects that facilitate the surgical procedure.
  • In this study, our aim is to discuss the problems encountered in different resection and reconstruction approaches in childhood bone and soft tissue tumors, and the recommended solutions addressed to these problems.
  • The lesions of 34 patients were detected to be in distal femur, 26 in proximal tibia and fibula, 4 in foot and ankle joint, and the remaining 4 in pelvis.
  • Limb salvage surgery has been considered as the gold standard treatment in orthopedic oncological surgery.
  • Since some problems are still encountered, we offer a therapeutic algorithm for complications in the management of childhood tumors that we have encountered so far.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Control. 2001 Jul-Aug;8(4):344-8 [11483888.001]
  • [Cites] World J Surg Oncol. 2004;2:22 [15230975.001]
  • [Cites] Oncologist. 2006 May;11(5):503-19 [16720851.001]
  • [Cites] J Bone Joint Surg Br. 2006 Jan;88(1):95-9 [16365128.001]
  • [Cites] J Am Acad Orthop Surg. 2005 Dec;13(8):544-54 [16330516.001]
  • [Cites] J Bone Joint Surg Am. 2005 Nov;87(11):2449-55 [16264120.001]
  • [Cites] Acta Orthop Scand. 2002 Jan;73(1):85-8 [11928918.001]
  • [Cites] Croat Med J. 2004 Dec;45(6):740-5 [15578809.001]
  • [Cites] N Engl J Med. 1999 Jul 29;341(5):342-52 [10423470.001]
  • [Cites] J Bone Joint Surg Br. 1995 Mar;77(2):173-4 [7706326.001]
  • [Cites] Clin Orthop Relat Res. 1989 Oct;(247):67-73 [2676306.001]
  • [Cites] Clin Orthop Relat Res. 2003 Oct;(415):72-81 [14612632.001]
  • [Cites] Clin Orthop Relat Res. 2005 Sep;438:51-9 [16131869.001]
  • (PMID = 19957110.001).
  • [ISSN] 1828-8928
  • [Journal-full-title] Strategies in trauma and limb reconstruction (Online)
  • [ISO-abbreviation] Strategies Trauma Limb Reconstr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2839316
  •  go-up   go-down


9. Wessalowski R, Schneider DT, Mils O, Hannen M, Calaminus G, Engelbrecht V, Pape H, Willers R, Engert J, Harms D, Göbel U: An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors. Klin Padiatr; 2003 Nov-Dec;215(6):303-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An approach for cure: PEI-chemotherapy and regional deep hyperthermia in children and adolescents with unresectable malignant tumors.
  • BACKGROUND: Elevated temperatures of 40 - 44 degrees C increase the actions of various anticancer drugs including N-lost derivatives, cytotoxic antibiotics and platinum analoga.
  • In clinical usage thermochemotherapy (TCH) should facilitate surgical resection and ameliorate local tumor control.
  • Among these, 24 patients had extracranial non-testicular germ cell tumors and 15 patients soft tissue or chondrosarcomas.
  • INDICATION: locoregional relapse (n = 29) or unresectable tumor after neoadjuvant chemotherapy (n = 10).
  • Among these two groups, there were ten patients with poor response or progressive disease under primary or relapse chemotherapy.
  • Tumor site: pelvis (30), abdomen (4), head and neck (2), proximal leg (2) and lumbar spine (1).
  • TCH was followed by surgical tumor resection in 28/39 patients and/or radiotherapy in 13/39 patients.
  • CONCLUSION: TCH shows substantial therapeutic efficacy and facilitates complete tumor resection in 14 out of 28 operated patients.
  • Multimodal treatment including TCH, surgical resection and/or radiotherapy leads to sustained remission in the majority of patients with locoregional tumor recurrence.
  • The therapeutic effect is most pronounced, if TCH is administered at first relapse.
  • Therefore, a more valid assessment of treatment efficacy can only be made by a matched-pair comparison in cooperation with the clinical registers.
  • [MeSH-major] Abdominal Neoplasms / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / therapy. Chondrosarcoma / therapy. Cisplatin / therapeutic use. Etoposide / therapeutic use. Germinoma / therapy. Head and Neck Neoplasms / therapy. Hyperthermia, Induced. Ifosfamide / therapeutic use. Lumbar Vertebrae. Pelvic Neoplasms / therapy. Sarcoma / therapy. Soft Tissue Neoplasms / therapy. Spinal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Chemotherapy, Adjuvant. Chi-Square Distribution. Child. Child, Preschool. Combined Modality Therapy. Data Interpretation, Statistical. Female. Follow-Up Studies. Humans. Infant. Karnofsky Performance Status. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local. Time Factors. Treatment Outcome


10. Martin RC 2nd, Brennan MF: Adult soft tissue Ewing sarcoma or primitive neuroectodermal tumors: predictors of survival? Arch Surg; 2003 Mar;138(3):281-5
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult soft tissue Ewing sarcoma or primitive neuroectodermal tumors: predictors of survival?
  • The improvement in survival is primarily associated with the combination of surgery and chemotherapy.
  • HYPOTHESIS: Little is known about the outcome of adults with soft tissue ES or primitive neuroectodermal tumors (PNET).
  • Certain prognostic factors from soft tissue sarcomas (tumor size, tumor location, margin status, and initial presentation) in adults (>16 years) with ES/PNET will help to identify factors associated with outcome.
  • METHODS: Between July 1, 1982, and June 30, 2000, we identified 59 adult patients with primary soft tissue ES/PNET.
  • Clinicopathologic factors were correlated with the end points studied: patient factors, tumor factors, pathologic factors, status of surgical margins, adjuvant chemotherapy, and radiation therapy.
  • Median tumor size was 8 cm, with all lesions being high grade.
  • The most common site was the trunk (n = 22), with an even distribution of retroperitoneal, pelvis, buttock, and lower extremity (all n = 5).
  • The median follow-up was 29 months (range, 6-222 months), with local recurrence identified in 13 patients (22%), with a median time to recurrence of 15 months (range, 5-200 months).
  • Initial presentation was the only predictor of long-term survival, with primary tumor-only presentation having a 5-year survival of 60% (median not reached) compared with primary tumor plus metastatic disease having a 5-year survival of 33% (median, 17 months) (P =.02).
  • [MeSH-major] Neuroectodermal Tumors, Primitive, Peripheral / mortality. Sarcoma, Ewing / mortality. Soft Tissue Neoplasms / mortality
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12611575.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Tran PT, Hara W, Su Z, Lin HJ, Bendapudi PK, Norton J, Teng N, King CR, Kapp DS: Intraoperative radiation therapy for locally advanced and recurrent soft-tissue sarcomas in adults. Int J Radiat Oncol Biol Phys; 2008 Nov 15;72(4):1146-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative radiation therapy for locally advanced and recurrent soft-tissue sarcomas in adults.
  • PURPOSE: To analyze the outcomes of and identify prognostic factors for patients treated with surgery and intraoperative radiotherapy (IORT) for locally advanced and recurrent soft-tissue sarcoma in adults from a single institution.
  • Primary sites included retroperitoneum-pelvis (78%), extremity (8%), and other (14%).
  • Clinical characteristics were as follows: mean tumor size, 10 cm (range, 1-25 cm); high-grade histologic subtype (72%); and mean dose, 1,159 cGy (range, 600-1,600 cGy).
  • Postoperative radiation or chemotherapy was administered to 37% of IORT Sites and 32% of patients, respectively.
  • Outcomes measured were infield control (IFC), locoregional control (LRC), distant metastasis-free survival (DMFS), disease-specific survival (DSS), and treatment-related complications.
  • Prognostic factors found to be significant (p < 0.05) on multivariate analysis were prior DFI and tumor size for LRC, extremity location and leiomyosarcoma histologic subtype for DMFS, and prior DFI for DSS.
  • Our cohort had five Grade 3/4 complications associated with treatment or a 5-year Kaplan-Meier Grade 3/4 complication-free survival rate of 85%.
  • CONCLUSIONS: IORT after tumor reductive surgery is well tolerated and seems to confer IFC in carefully selected patients.
  • [MeSH-major] Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Sarcoma / radiotherapy. Sarcoma / surgery. Soft Tissue Neoplasms / radiotherapy. Soft Tissue Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394818.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Siva Prasad G, Chacko KN, Antony D, Lionel G, Kekre NS, Gopalakrishnan G: Bladder-sparing surgery in locally advanced nonurological pelvic malignancy. Urol Int; 2006;77(1):18-21
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Often a dilemma exists between cystectomy and a bladder-sparing procedure.
  • 10 had locally advanced colorectal malignancy, 3 with soft tissue masses of the lateral pelvic wall, 1 had ovarian malignancy and the other had residual mass following radiotherapy and chemotherapy of cancer cervix.
  • Urine examination and ultrasonography was not helpful in suggesting bladder involvement, unlike CT scan of abdomen and pelvis.
  • Palliative transurethral resection was done in 1 patient with tumor infiltration at the bladder neck and prostate.
  • Preoperative CT scan or MRI can predict lower urinary tract involvement and help in decision-making by both surgeon and patient.
  • The ultimate decision for bladder sparing is based on intraoperative findings.
  • [MeSH-major] Colorectal Neoplasms / surgery. Ovarian Neoplasms / surgery. Soft Tissue Neoplasms / surgery. Uterine Cervical Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825810.001).
  • [ISSN] 0042-1138
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


13. Petković M, Zamolo G, Muhvić D, Coklo M, Stifter S, Antulov R: The first report of extraosseous Ewing's sarcoma in the rectovaginal septum. Tumori; 2002 Jul-Aug;88(4):345-6
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ewing's sarcoma is a highly malignant neoplasm of bone, which usually occurs during childhood.
  • The mass had a size of 9 x 6 cm, a soft tissue consistency, was partially movable and the patient felt the pain during palpation.
  • Computed tomography (CT) showed an inhomogeneous expansive mass in the rectovaginal septum measuring 8.7 x 6.1 cm, without any signs of rectum or bladder invasion.
  • The vascular structures of the pelvis were normal.
  • At laparotomy the process was judged inoperable and only biopsy of the tumor mass was carried out.
  • Histology showed a neoplasm with small, round to oval cells with scarce cytoplasm.
  • The patient was treated with chemotherapy followed by whole-pelvis external beam radiation and intracavitary brachytherapy.
  • RESULTS: A residual mass measuring 3.5 x 2.5 cm was visible on a control CT scan 18 months after treatment; however, the patient was feeling well and refused surgery to remove the residual mass.
  • [MeSH-major] Rectal Neoplasms / therapy. Sarcoma, Ewing / therapy. Vaginal Neoplasms / therapy

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12400989.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Dujardin F, Bocquet G, Debled M, Cambon-Michot C, Vera P, Patricot B, Thomine JM: [Primary intraosseous rhabdomyosarcoma]. Rev Chir Orthop Reparatrice Appar Mot; 2000 May;86(3):293-9
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a case of primary intraosseous pleiomorphic rhabdomyosarcoma located in the pelvis of a 21-year-old woman followed for 4 years.
  • The lytic tumor involved the acetabulum and the isthma with moderate extension to soft tissue.
  • First line chemotherapy was unable to arrest tumor progression.
  • Recurrence-free remission was achieved for 4 years, suggesting this was indeed a primary tumor.
  • Bone localizations generally suggest metastasis from a primary tumor often situated in an intraperitoneal localization.
  • When search for a primary tumor is negative, intraosseous lesions can be considered as primary tumors warranting curative treatment.
  • Radical surgical resection is recommended within the framework of a multidiscipinary management protocol associating radiotherapy and chemotherapy to improve prognosis.
  • [MeSH-minor] Adult. Bone Transplantation. Combined Modality Therapy. Female. Humans. Neoadjuvant Therapy. Prosthesis Implantation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Chir Orthop Reparatrice Appar Mot 2002 Oct;88(6):638
  • (PMID = 10844360.001).
  • [ISSN] 0035-1040
  • [Journal-full-title] Revue de chirurgie orthopédique et réparatrice de l'appareil moteur
  • [ISO-abbreviation] Rev Chir Orthop Reparatrice Appar Mot
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] FRANCE
  •  go-up   go-down


15. Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vande Berg B, Lecouvet FE: Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate; 2005 Oct 1;65(2):178-87
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases.
  • Here, we assessed the value of MRI of the axial skeleton (AS-MRI) as a single step technique to quantify bone metastases and measure tumor response.
  • METHODS: AS-MRI was performed in 38 patients before receiving chemotherapy for metastatic HRPCa, in addition to PSA, computed tomography of the thorax, abdomen, and pelvis [CT-TAP]; and Tc-99m bone scintigraphy.
  • A second AS-MRI was performed in 20 patients who completed 6 months of chemotherapy.
  • Evaluation of tumor response was performed using RECIST.
  • RESULTS: Only 11 patients (29%) had RECIST measurable metastases in soft-tissues or lymph nodes on baseline CT-TAP.
  • Transposing RECIST on AS-MRI in 20 patients who completed 6 months of treatment, allows the accurate estimation of complete response (n = 2), partial response (n = 2), stable disease (n = 5), or tumor progression (n = 11), as it is done using CT-TAP in soft tissue solid metastases.
  • CONCLUSIONS: MRI of axial skeleton enables precise measurement and follow-up of bone metastases as it is for other soft-tissue metastasis.
  • [MeSH-minor] Endpoint Determination. Humans. Male. Prospective Studies. Treatment Outcome


16. Lal DR, Su WT, Wolden SL, Loh KC, Modak S, La Quaglia MP: Results of multimodal treatment for desmoplastic small round cell tumors. J Pediatr Surg; 2005 Jan;40(1):251-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of multimodal treatment for desmoplastic small round cell tumors.
  • We examined the effects of multimodal therapy including induction chemotherapy, aggressive surgical debulking, and external beam radiotherapy on patients with DSRCT.
  • Data were collected on patient demographics, presenting symptoms, tumor location and extent, treatment regimen, and overall survival.
  • RESULTS: A majority of patients were male (91%), Caucasian (85%), and with a median age of 19 (7-58) years old at diagnosis.
  • In 63 patients (96%), the primary tumor was located in the abdomen or pelvis.
  • Thirty-three (50%) had positive lymph nodes and 27 (41%) had distant parenchymal metastases at diagnosis.
  • Twenty-nine of these patients (44%) underwent induction chemotherapy (P6), surgical debulking, and radiotherapy.
  • Three-year survival was 55% in those receiving chemotherapy, surgery, and radiotherapy vs 27% when all 3 modalities were not used (P < .02).
  • Gross tumor resection was highly significant in prolonging overall survival; 3-year survival was 58% in patients treated with gross tumor resection compared to no survivors past 3 years in the nonresection cohort (P < .00001).
  • CONCLUSIONS: Multimodal therapy results in improved survival in patients with DSRCT.
  • [MeSH-major] Sarcoma, Small Cell / therapy. Soft Tissue Neoplasms / therapy
  • [MeSH-minor] Abdominal Neoplasms / pathology. Abdominal Neoplasms / surgery. Abdominal Neoplasms / therapy. Adolescent. Adult. Antineoplastic Agents / therapeutic use. Child. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Pelvic Neoplasms / pathology. Pelvic Neoplasms / surgery. Pelvic Neoplasms / therapy. Radiotherapy. Surgical Procedures, Operative. Survival Analysis. Testicular Neoplasms / pathology. Testicular Neoplasms / surgery. Testicular Neoplasms / therapy. Thoracic Neoplasms / pathology. Thoracic Neoplasms / surgery. Thoracic Neoplasms / therapy. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868593.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


17. Eroğlu A, Kürkçüoğlu IC, Karaoğlanoğlu N, Alper F, Gündoğdu C: Extraskeletal Ewing sarcoma of the diaphragm presenting with hemothorax. Ann Thorac Surg; 2004 Aug;78(2):715-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ewing sarcoma is a relatively uncommon malignant bone neoplasm that usually occurs in children and young adults and involves the major long bones, pelvis, and ribs.
  • After drainage, a roentgenogram film, computed tomography, ultrasonography, and magnetic resonance image showed a giant mass on the right diaphragm.
  • Primary diaphragmatic tumor was resected totally by right posterolateral thoracotomy, and histologically, an extraskeletal Ewing sarcoma was identified.
  • The patient received adjuvant radio-chemotherapy, and there was no evidence of disease 10 months after the operation.
  • Although extremely rare, extraskeletal Ewing sarcoma should be kept in mind in the differential diagnosis of diaphragmatic soft tissue tumors.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Child. Combined Modality Therapy. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Dyspnea / etiology. Female. Hemothorax / etiology. Humans. Ifosfamide / administration & dosage. Mesna / administration & dosage. Neoplasm Invasiveness. Organ Specificity. Radiotherapy, Adjuvant. Remission Induction. Ribs / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15276562.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; MAID protocol
  •  go-up   go-down


18. Jeon IS, Yi DY: Acute lymphoblastic leukemia secondary to chemoradiotherapy for perivascular epithelioid cell tumor of uterus. Pediatr Hematol Oncol; 2009 Mar;26(2):85-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia secondary to chemoradiotherapy for perivascular epithelioid cell tumor of uterus.
  • Acute lymphoblastic leukemia (ALL), a primary hematologic malignancy that is especially common in childhood, occurs relatively rarely as a secondary malignant neoplasm.
  • Available data indicate that ALL often follows chemoradiotherapy for soft tissue sarcoma.
  • Perivascular epithelioid tumor (PEComa), a primitive mesenchymal tissue origin, can be classified as a soft tissue sarcoma.
  • An 11-year-old girl was diagnosed with ALL secondary to chemoradiotherapy (vincristine, ifosfamide, and anthracycline) and radiotherapy comprising 45 Gy to the whole pelvis for PEComa.
  • ALL, FAB L2, and immunophenotypically pro-B developed 16 months after the final chemotherapy treatment.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19322738.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Topoisomerase II Inhibitors
  •  go-up   go-down


19. Paulino AC, Mayr NA, Simon JH, Buatti JM: Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity. Int J Radiat Oncol Biol Phys; 2002 Mar 15;52(4):1025-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity.
  • Primary tumor was located in the adrenal gland in 26 (49%), abdomen/nonadrenal in 14 (26%), thorax in 9 (17%), neck in 2 (4%), and pelvis in 2 (4%).
  • All patients, except 11 with Stage 4S and 4 with Stage 4, had resection of the primary tumor.
  • Postoperative doses ranged from 15 to 25 Gy whereas preoperative doses ranged from 12 to 31 Gy using a median fraction size of 1.5 Gy.
  • Chemotherapy was employed in 22 of 53 patients (42%) with the most common agents being cyclophosphamide in 22 and doxorubicin in 11.
  • RESULTS: Tumor control: The 5-year overall and freedom from progression rates were 79 +/- 9% and 81 +/- 11%; the locoregional control rate was 88 +/- 9%.
  • Five of 6 infants <6 months of age and 1 of 7 >/=6 months developed musculoskeletal toxicity.
  • Musculoskeletal effects were seen in 6 RT patients and included bony hypoplasia in 6, scoliosis in 5, soft tissue hypoplasia in 3, slipped capital femoral epiphysis in 2, kyphosis in 1, and osteochondroma in 1.
  • Three required orthopedic intervention, all receiving >/=20 Gy.
  • One child developed bowel obstruction at 21 months and another developed a leiomyosarcoma in the treatment field 34 years after RT.
  • [MeSH-minor] Abdominal Neoplasms / mortality. Abdominal Neoplasms / pathology. Abdominal Neoplasms / radiotherapy. Combined Modality Therapy. Disease Progression. Female. Humans. Infant. Infant, Newborn. Lymphatic Metastasis. Male. Musculoskeletal Diseases / etiology. Neoplasm Staging. Pelvic Neoplasms / mortality. Pelvic Neoplasms / pathology. Pelvic Neoplasms / radiotherapy. Radiation Injuries / complications. Survival Rate. Thoracic Neoplasms / mortality. Thoracic Neoplasms / pathology. Thoracic Neoplasms / radiotherapy. Treatment Failure

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1575; author reply 1575 [12459387.001]
  • (PMID = 11958898.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Antic D, Verstovsek S, Elezovic I, Grujicic D, Gotic M, Bila J, Perunicic M, Jakovic L: Spinal epidural granulocytic sarcoma in non-leukemic patient. Int J Hematol; 2009 Jan;89(1):95-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Magnetic resonance imaging of the spine showed a large soft tissue mass infiltrating paraspinal musculature of lumbosacral area, sacral laminas, last lumbar and all sacral vertebra, protruding into the spinal canal, and with propagation into pelvis.
  • Decompressive laminectomy and tumor removal were performed resulting in neurological improvement.
  • The patient underwent adjuvant chemotherapy and radiotherapy, resulting in the elimination of residual lesion, followed by autologous transplant.
  • Immediate diagnosis and adequate systematic treatment are essential to achieve optimal results in patients with isolated GS.
  • The patient is alive and free of the disease 14 months from the diagnosis.
  • [MeSH-major] Epidural Neoplasms / therapy. Sarcoma, Myeloid / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Mar 15;94(6):1739-46 [11920536.001]
  • [Cites] Cancer. 1981 Sep 15;48(6):1426-37 [7023656.001]
  • [Cites] Int J Hematol. 2008 Jul;88(1):101-3 [18498027.001]
  • [Cites] Leukemia. 2003 Jun;17(6):1100-3 [12764375.001]
  • [Cites] Int J Clin Oncol. 2007 Jun;12(3):234-7 [17566850.001]
  • [Cites] Neurol Med Chir (Tokyo). 2008 Mar;48(3):131-6 [18362461.001]
  • [Cites] J Clin Oncol. 2008 Oct 20;26(30):4940-3 [18606981.001]
  • [Cites] Leuk Lymphoma. 2003 Oct;44(10):1753-60 [14692530.001]
  • [Cites] Leukemia. 2007 Feb;21(2):340-50 [17170724.001]
  • [Cites] Int J Hematol. 2008 May;87(4):410-3 [18365139.001]
  • [Cites] Br J Haematol. 2008 Apr;141(2):134 [18353162.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1800-16 [7602369.001]
  • (PMID = 19109732.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


21. Duet M, Kerkeni S, Sfar R, Bazille C, Lioté F, Orcel P: Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia. Clin Nucl Med; 2008 Nov;33(11):752-6
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia.
  • OBJECTIVE: Tumor-induced osteomalacia (TIO) is a rare condition due to phosphate wasting secondary to the release of a phosphatonin, fibroblast growth factor-23.
  • Attempts to identify the tumor by physical examination and/or conventional imaging are sometimes unrewarding.
  • METHODS: Two case reports and a review of the literature allow to demonstrate the diagnostic usefulness of octreotide and the therapeutic value of somatostatin.
  • In one of our patients with incomplete removal of the tumor, octreotide therapy was unable to improve hypophosphatemia, despite a decrease in fibroblast growth factor-23 levels by 30%.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / radionuclide imaging. Bone Neoplasms / drug therapy. Bone Neoplasms / radionuclide imaging. Octreotide / therapeutic use. Osteomalacia / radionuclide imaging. Receptors, Somatostatin / agonists. Receptors, Somatostatin / antagonists & inhibitors. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Angiolipoma / complications. Angiolipoma / drug therapy. Angiolipoma / radionuclide imaging. Angiolipoma / surgery. Fibroblast Growth Factors / drug effects. Fibroblast Growth Factors / metabolism. Foot / pathology. Foot / radionuclide imaging. Hip / pathology. Hip / radionuclide imaging. Humans. Hypophosphatemia / drug therapy. Hypophosphatemia / etiology. Knee / pathology. Knee / radionuclide imaging. Male. Middle Aged. Paraneoplastic Syndromes / complications. Paraneoplastic Syndromes / radionuclide imaging. Pelvis / pathology. Pelvis / radionuclide imaging. Phosphates / metabolism. Phosphates / therapeutic use. Radionuclide Imaging / methods. Ribs / pathology. Ribs / radionuclide imaging. Somatostatin / analogs & derivatives. Somatostatin / pharmacokinetics. Somatostatin / therapeutic use. Whole Body Imaging

  • Genetic Alliance. consumer health - Osteomalacia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936605.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Phosphates; 0 / Receptors, Somatostatin; 0 / fibroblast growth factor 23; 51110-01-1 / Somatostatin; 62031-54-3 / Fibroblast Growth Factors; G083B71P98 / pentetreotide; RWM8CCW8GP / Octreotide
  •  go-up   go-down


22. Baz W, El-Soueidi R, Nakhl F, Aoun N, Chin N, Dhar M: Desmoplastic small round-cell tumor: an adult with previous exposure to agent orange. Jpn J Clin Oncol; 2010 Jun;40(6):593-5
Hazardous Substances Data Bank. 2,4-D .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic small round-cell tumor: an adult with previous exposure to agent orange.
  • Desmoplastic small round-cell tumor is an uncommon, highly aggressive tumor with a predilection for pediatric age groups and young adults.
  • Although Agent Orange has been associated with soft-tissue sarcoma, an association with desmoplastic small round-cell tumor has not been reported.
  • Computed tomography scan of the chest, abdomen and pelvis demonstrated extensive mediastinal and retroperitoneal adenopathy, diffuse omental masses and extensive pleural, intra-abdominal and pelvic ascites.
  • Omental core needle biopsy was consistent with desmoplastic small round-cell tumor based on morphology and immunohistochemistry.
  • He responded poorly to chemotherapy with high-dose cyclophosphamide, doxorubicin and vincristine and died 5 months after presentation secondary to neutropenic sepsis despite G-CSF support and antibiotics.

  • Genetic Alliance. consumer health - Desmoplastic Small Round Cell Tumor.
  • Hazardous Substances Data Bank. 2,4,5-T .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20382635.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Defoliants, Chemical; 2577AQ9262 / 2,4-Dichlorophenoxyacetic Acid; 39277-47-9 / Agent Orange; 9Q963S4YMX / 2,4,5-Trichlorophenoxyacetic Acid; DO80M48B6O / Tetrachlorodibenzodioxin
  •  go-up   go-down


23. Hadfield MG, Quezado MM, Williams RL, Luo VY: Ewing's family of tumors involving structures related to the central nervous system: a review. Pediatr Dev Pathol; 2000 May-Jun;3(3):203-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These tumors involve the skull, the spinal column, adjacent soft tissues, the meninges, and the brain.
  • We have separated the cases by skull region and spinal column level, and we discuss the attendant differences in prognosis following treatment by neurosurgery, radiation, and chemotherapy.
  • Light and electron microscopic features can be used to differentiate EFT from other small round blue cell tumors that involve the CNS (central primitive neuroectodermal tumor, lymphoma, etc.).
  • We conclude that EFT involving the CNS and adjacent structures is not so rare as previously stated and that the prognosis is more favorable, as a rule, than for the more common examples arising in the long bones and pelvis.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Sarcoma, Ewing / diagnosis
  • [MeSH-minor] Adolescent. Child. Diagnosis, Differential. Epidural Neoplasms / diagnosis. Female. Genetic Techniques. Humans. Immunohistochemistry. Infant. Jaw Neoplasms / diagnosis. Male. Microscopy, Electron. Neuroectodermal Tumors, Primitive / diagnosis. Prognosis. Skull Neoplasms / diagnosis. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / secondary. Spinal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10742406.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 122
  •  go-up   go-down


24. Singh AK, Myerson RJ, Birnbaum EH, Fleshman JW, Kodner IJ, Lockett MA, Read TE: Outcome of patients with rectal adenocarcinoma and localized pelvic non-nodal metastatic foci. Dis Colon Rectum; 2000 Sep;43(9):1217-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The aim of this study was to evaluate the outcome of patients with primary rectal adenocarcinoma and soft tissue metastatic foci restricted to the pelvis and to determine whether this entity, which is considered N1 disease in the American Joint Committee on Cancer staging system, behaves like completely replaced nodal disease or the first sign of M1 disease.
  • METHODS: The authors retrospectively reviewed the medical records of 395 patients with rectal adenocarcinoma who received radiation treatment.
  • Eighteen patients had pelvic soft tissue metastatic foci.
  • Eight cases received chemotherapy.
  • Thirteen patients had lymph nodes that contained metastatic disease and would therefore have been scored N1 or N2 even without the pelvic tumor implants.
  • Sixteen of 18 (89 percent) patients died of disease after a survival time of 12 to 37 (mean, 25) months.
  • The other remaining survivor was undergoing palliative therapy for metastatic disease to the lung.
  • No other factor, including radiation dose, margin status, chemotherapy, T stage, and number of involved nodes or soft tissue implants, correlated independently with outcome.
  • Although this entity probably represents M1 disease for most patients, survival can be long, and aggressive locoregional and systemic treatment is warranted.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Pelvic Neoplasms / secondary. Rectal Neoplasms / therapy. Soft Tissue Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11005486.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


25. Chow E, Merchant TE, Pappo A, Jenkins JJ, Shah AB, Kun LE: Cutaneous and subcutaneous Ewing's sarcoma: an indolent disease. Int J Radiat Oncol Biol Phys; 2000 Jan 15;46(2):433-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The occurrence of extraosseous Ewing's sarcoma (ES) in deep soft tissues has been well described, but cases in which this tumor occurs in a primary cutaneous or subcutaneous site have rarely been reported.
  • The superficial variant may be less aggressive than are the more common bony and deep soft tissue counterparts with an apparently favorable outcome.
  • Anatomic locations included trunk and pelvis (7), upper or lower extremity (4), and head and neck (3).
  • Thirteen had definitive surgical resections, and one had biopsy of the mass at the time of referral.
  • All patients received chemotherapy, composed of vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, and dactinomycin.
  • Patients on institutional protocols received radiation (36 Gy) to the operative bed (150-180 cGy/fraction/day).
  • Thirteen patients had wide local excision of the primary tumors prior to enrollment on chemotherapy; surgical margins were negative (10), microscopically positive (2), and indeterminate (1).
  • Eleven patients received radiotherapy to the tumor bed; 2 with clear surgical margins were treated without irradiation.
  • The patient who had biopsy only received induction chemotherapy followed by definitive surgical resection and postoperative radiotherapy.
  • None of the patients has developed local recurrence or distant metastasis.
  • Several of the patients developed treatment-related sequelae, including veno-occlusive disease of the lung and hemorrhagic cystitis (1), myelodysplastic syndrome (1), chemotherapy-induced ovarian failure (1), moist desquamation (1), and dermatofibroma within the radiotherapy volumes (1).
  • CONCLUSIONS: Cutaneous and subcutaneous ES are associated with an indolent course and a favorable prognosis when treated with combined modality therapy.
  • Elimination of radiation therapy following complete resection has been tested in the POG 9354 trial.
  • The high rate of local control, low rate of metastatic disease, and excellent overall outcome may suggest a role for less intensive chemotherapy, as well as tailoring to diminish or avoid radiation therapy in completely resected cases, with a goal to minimize toxicity while maintaining a high cure rate.
  • [MeSH-minor] Adolescent. Adult. Child. Combined Modality Therapy. Female. Humans. Male. Retrospective Studies

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10661351.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA 21765
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  •  go-up   go-down


26. Blattmann C, Oertel S, Schulz-Ertner D, Rieken S, Haufe S, Ewerbeck V, Unterberg A, Karapanagiotou-Schenkel I, Combs SE, Nikoghosyan A, Bischof M, Jäkel O, Huber P, Kulozik AE, Debus J: Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer; 2010 Mar 12;10:96
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma.
  • BACKGROUND: Osteosarcoma is the most common primary malignant bone tumor in children and adolescents.
  • For effective treatment, local control of the tumor is absolutely critical, because the chances of long term survival are <10% and might effectively approach zero if a complete surgical resection of the tumor is not possible.
  • Up to date there is no curative treatment protocol for patients with non-resectable osteosarcomas, who are excluded from current osteosarcoma trials, e.g. EURAMOS1.
  • Generally the radiation dose that is necessary for a curative approach can hardly be achieved with conventional photon radiotherapy in patients with non-resectable tumors that are usually located near radiosensitive critical organs such as the brain, the spine or the pelvis.
  • In these cases particle Radiotherapy (proton therapy (PT)/heavy ion therapy (HIT) may offer a promising new alternative.
  • Moreover, compared with photons, heavy ion beams provide a higher physical selectivity because of their finite depth coverage in tissue.
  • Phase I/II dose escalation studies of HIT in adults with non-resectable bone and soft tissue sarcomas have already shown favorable results.
  • Desired target dose is 60-66 Cobalt Gray Equivalent (Gy E) with 45 Gy PT (proton therapy) and a carbon ion boost of 15-21 GyE.
  • Weekly fractionation of 5-6 x 3 Gy E is used.
  • Systemic disease before and after PT/HIT is targeted by standard chemotherapy protocols and is not part of this trial.
  • Secondary objectives are tumor response, disease free survival and overall survival.
  • [MeSH-minor] Adolescent. Adult. Child. Disease Progression. Disease-Free Survival. Heavy Ions. Humans. Ions. Protons. Research Design. Safety. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):179-81 [10655425.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1279-87 [10778952.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Sep 1;51(1):87-93 [11516856.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3277-84 [12115361.001]
  • [Cites] J Clin Oncol. 2002 Nov 15;20(22):4466-71 [12431970.001]
  • [Cites] Orthopade. 2003 Nov;32(11):940-8 [14615843.001]
  • [Cites] Clin Cancer Res. 2004 Mar 1;10(5):1764-72 [15014030.001]
  • [Cites] Med Pediatr Oncol. 1995 Jan;24(1):6-12 [7968796.001]
  • [Cites] Clin Orthop Relat Res. 1998 Mar;(348):196-207 [9553553.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1215-20 [9607579.001]
  • [Cites] J Bone Joint Surg Br. 1999 Sep;81(5):796-802 [10530839.001]
  • [Cites] Radiother Oncol. 2004 Dec;73 Suppl 2:S53-6 [15971310.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jun 1;68(2):449-57 [17363188.001]
  • [Cites] J Radiat Res. 2007;48 Suppl A:A1-A13 [17513896.001]
  • [Cites] J Radiat Res. 2007;48 Suppl A:A87-95 [17513904.001]
  • (PMID = 20226028.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT01005043
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ions; 0 / Protons
  • [Other-IDs] NLM/ PMC2846886
  •  go-up   go-down


27. Weber K, Damron TA, Frassica FJ, Sim FH: Malignant bone tumors. Instr Course Lect; 2008;57:673-88
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant bone tumors represent a small percentage of cancers nationwide and also are much less common than malignant soft-tissue tumors.
  • The rarity of the condition makes it imperative that orthopaedic surgeons in nononcologic practices are able to recognize the symptoms that suggest a possible bony malignancy to avoid inappropriate or delayed treatment.
  • The primary symptom of a patient with a malignant bone tumor is pain, which often occurs at rest or at night.
  • Patients with a likely malignancy require thorough staging to determine the extent of disease and a well-planned biopsy for accurate diagnosis.
  • Knowledge of specific tumor characteristics and treatment options for osteosarcoma, Ewing's sarcoma, chondrosarcoma, malignant fibrous histiocytoma, chordoma, and adamantinoma is important.
  • Patients with osteosarcoma and resectable Ewing's sarcoma are treated with chemotherapy followed by surgical resection.
  • Secondary sarcomas can occur in previously benign bone lesions and require aggressive treatment.
  • Specific techniques are available for the resection of malignant bone tumors from the upper extremities, lower extremities, pelvis, and spine.
  • The care of patients with primary malignant bone tumors requires a multidisciplinary approach to treatment.
  • [MeSH-minor] Global Health. Humans. Morbidity. Neoplasm Staging / methods. Prognosis

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18399615.001).
  • [ISSN] 0065-6895
  • [Journal-full-title] Instructional course lectures
  • [ISO-abbreviation] Instr Course Lect
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


28. Ricke J, Sehouli J, Hach C, Hänninen EL, Lichtenegger W, Felix R: Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol; 2003 May;13(5):943-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The purpose of this study was to assess the accuracy of MRI in the staging of intra-abdominal tumor seeding of ovarian carcinoma.
  • The MRI protocol included fat-saturated T1-weighted spin-echo (SE) sequences pre- and post i.v. application of gadopentetate dimeglumine.
  • The criteria for tumor manifestation was contrast enhancement of intra-abdominal soft tissue lesions or peritoneum.
  • Laparotomy and histopathology confirmed 251 abdominal tumor locations.
  • Sensitivity was high in lower pelvis locations (73-83%) except for ureter or bladder infiltration (40%).
  • Magnetic resonance imaging based on contrast-enhanced fat-saturated T1 SE sequences improves planning of cytoreduction preceding chemotherapy in advanced primary or relapsed ovarian carcinoma.
  • [MeSH-minor] Abdominal Neoplasms / diagnosis. Abdominal Neoplasms / secondary. Adult. Aged. Aged, 80 and over. False Positive Reactions. Female. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / secondary. Genital Neoplasms, Female / diagnosis. Genital Neoplasms, Female / secondary. Humans. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Recurrence, Local. Neoplasms, Second Primary. Pelvic Neoplasms / diagnosis. Pelvic Neoplasms / secondary. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Single-Blind Method. Women's Health

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12695813.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down






Advertisement